| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015117551 |
| Title |
Pyrrole-Substituted Indolone Derivative, Preparation Method Therefor, Composition Comprising Same and Use Thereof. |
| Abstract |
The present invention relates to a pyrrole-substituted indolone derivative, a preparation method therefor, a composition comprising same and a use thereof. The pyrrole-substituted indolone derivative. |
| Applicant(s) |
Shijiazhuang Yiling Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0A8SH |
Drug Info
|
IC50 = 65 nM |
Click to Show More |
[1] |
|
2
|
D0X2MF
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2012139019 |
| Title |
New Indolinone Protein Kinase Inhibitors. |
| Abstract |
The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer. |
| Applicant(s) |
Beta Pharma, Inc |
| Representative Drug(s) |
D0VX5Y |
Drug Info
|
IC50 = 65 nM |
Click to Show More |
[1] |
|
2
|
D0HO5B
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2014086102 |
| Title |
Indole Full Ketone Derivative Used As Tyrosine-Kinase Inhibitor. |
| Abstract |
The present invention relates to a compound having the general formula (I), a method of preparing the compound, a drug preparation containing the compound, and applications of the compound in preparin. |
| Applicant(s) |
Kbp Biosciences Co., Ltd |
| Representative Drug(s) |
D01DJZ |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0O8RZ
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2013032797 |
| Title |
Oxetane 3,3-Dicarboxamide Compounds and Methods of Making and Using Same. |
| Abstract |
A novel series of oxetane 3,3-dicarboxamide compounds modulate protein kinase activity for modulating cellular activities such as proliferation, migration, differentiation, and programmed cell death. This novel series of oxetane 3,3-dicarboxamide compounds may inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDR (VEGFR-2) signal transduction pathways, thereby make them useful as anti-cancer agents. The pharmaceutical compositions that comprise these compounds are also useful in the treatment of diseases, other than cancers, which are associated with signal transduction pathways operating through growth factor and anti-angiogenesis receptors, such as c-Met, and KDR (VEGFR-2). |
| Applicant(s) |
New Hope R & D Bioscience, Inc |
| Representative Drug(s) |
D03VXQ |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0ZE2J
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2012088506 |
| Title |
Polymer-Semaxanib Moiety Conjugates. |
| Abstract |
The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form. |
| Applicant(s) |
Nektar Therapeutics |
| Representative Drug(s) |
D0E5IJ |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0Z0SY
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2016059057 |
| Title |
Vegfr-2 Binding Polypeptides. |
| Abstract |
The present disclosure relates to a class of engineered polypeptides having a binding affinity for vascular endothelial growth factor receptor 2 (VEGFR-2), and provides a VEGFR-2 binding polypeptide comprising the sequence ENX 3 X 4 ASX 7 EIAX 11 LPNLX 16 DX 18 QYIAFIYX 26 LLX 29. The present disclosure also relates to the use of such a VEGFR-2 binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent. |
| Applicant(s) |
Affibody Ab |
| Representative Drug(s) |
D01IFD |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2016044219 |
| Title |
Therapeutic and Research Application of Pdcl3. |
| Abstract |
Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis. |
| Applicant(s) |
Trustees of Boston University |
| Representative Drug(s) |
D0WL5P |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015089220 |
| Title |
Substituted Nicotinamide Derivatives As Kinase Inhibitors. |
| Abstract |
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D07AVU |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015075483 |
| Title |
1 -(5-Tert-Butyl-2-Aryl-Pyrazol-3-Yl)-3-[2-Fluoro-4-[(3-Oxo-4H-Pyrido[2, 3-B]Pyrazin-8-Yl)Oxy]Phenyl]Urea Derivatives As Raf Inhibitors for The Treatment of Cancer. |
| Abstract |
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)- 3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea compounds (referred herein as "TBAP compounds") that, inter alia, inhibit RAF (e.g., BRAF, CRAF, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF, CRAF, etc.); and to treat disorders including: proliferative disorders; cancer (including, e.g., malignant melanoma, colorectal carcinoma, pancreatic adenocarcinoma); inflammation; immunological disorders; viral infections; fibrotic disorders; disorders associated with a mutated form of RAF (e.g., BRAF, CRAF, etc.); disorders ameliorated by the inhibition of RAF (e.g., BRAF, CRAF, etc.); disorders ameliorated by the inhibition of mutant BRAF; disorders ameliorated by the inhibition of BRAF and CRAF; disorders associated with RAS mutations and/or MAPK pathway activation; disorders ameliorated by the inhibition of SRC, p38, FGFRA, VEGFR-2 (KDR), and/or LCK; etc. |
| Applicant(s) |
Cancer Research Technology Limited |
| Representative Drug(s) |
D0IZ8B |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014139458 |
| Title |
Fused Ring Compound Containing Pyrimidine or Pyridine and Use Thereof As Anti-Tumour Drug. |
| Abstract |
Disclosed in the invention are a fused ring compound containing pyrimidine or pyridine and the use thereof as an anti-tumour drug. teT fused ring compound is a compound as shown by formula (I) or a ph. |
| Applicant(s) |
Cisen Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0EE3P |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014127335 |
| Title |
Therapeutic Compounds and Uses Thereof. |
| Abstract |
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided. |
| Applicant(s) |
Kala Pharmaceuticals, Inc |
| Representative Drug(s) |
D0FK6Y |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014127214 |
| Title |
Therapeutic Compounds and Uses Thereof. |
| Abstract |
Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions hereof for treating diseases are also provided. |
| Applicant(s) |
Kala Pharmaceuticals, Inc |
| Representative Drug(s) |
D0SH2Y |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014113859 |
| Title |
2-Chloro-4-Anilino-Quinazoline Compounds Inhibiting Protein Tyrosine Kinases, Pharmaceutical Compositions Comprising The Same, Method for Producing The Same and Tyrosine Kinase Inhibition Method. |
| Abstract |
The present invention relates to 2-chloro-4-anilino-quinazoline derivatives with EGFR and/or VEGFR-2 protein tyrosine kinase inhibiting activity, to anti-tumour pharmaceutical compositions that comprise said compounds, and to methods for producing the same. The present invention further provides a method for treating solid tumours by inhibition of tyrosine kinases. |
| Applicant(s) |
Universidade Federal Do Rio De Janeiro |
| Representative Drug(s) |
D0FL6P |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014102377 |
| Title |
Azaindole Derivatives As Multi Kinase Inhibitors. |
| Abstract |
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders. |
| Applicant(s) |
Oribase Pharma |
| Representative Drug(s) |
D0Q4XV |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014081202 |
| Title |
Dual-Target Antibody Targeting Vegfr-2 and Dll4, and Pharmaceutical Composition Comprising Same. |
| Abstract |
The present invention relates to an antibody targeting VEGFR-2, and more particularly a dual-target antibody of novel form in which calcium-binding EGF-like domains 11 and 12 of human Notch1 are bound. |
| Applicant(s) |
Pharmabcine Inc |
| Representative Drug(s) |
D0U6PW |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014079545 |
| Title |
Thioether Derivatives As Protein Kinase Inhibitors. |
| Abstract |
The present invention relates to thioether derivatives (1) as protein kinase inhibitors, which are useful for the treatment, relieve and/or prevention of diseases associated with abnormal and hyperproliferation of cells in a mammal, especially humans, and which are particularly useful for the treatment of all forms of cancer. |
| Applicant(s) |
Ktb Tumorforschungsgesellschaft Mbh |
| Representative Drug(s) |
D0HX9S |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014055998 |
| Title |
Human Anti-Vegfr-2/Kdr Antibodies. |
| Abstract |
The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents. |
| Applicant(s) |
Kadmon Corporation, Llc |
| Representative Drug(s) |
D0CE1R |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014040242 |
| Title |
3-Chloro- and 3-Methoxy-N-Methyl-2-Pyridine Carboxamide Compound and Application Thereof As Anticancer Medicament. |
| Abstract |
Provided in the present invention is, as represented by formula (I), a 3-chloro and 3-methoxy-N-methyl-2-pyridine carboxamide compound for inhibiting kinases such as VEGFR-2. Also provided in the pres. |
| Applicant(s) |
Hunan Nonferrous Metals Group Chembio Pharmacy Co., Ltd |
| Representative Drug(s) |
D0FY2Q |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014029251 |
| Title |
Benazepine Compound and Application Thereof. |
| Abstract |
Disclosed are a benazepine compound and an application thereof. The benazepine compound, as a synthon for preparing a novel compound with an anti-tumor activity, results in a compound that has a signi. |
| Applicant(s) |
Cisen Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0KW0F |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014029250 |
| Title |
Benazepine Compound and Application Thereof. |
| Abstract |
Provided are a benazepine compound, a composition containing the compound and a use of the compound in the preparation of anti-tumor drugs. The benazepine compound is a compound shown in formula (I) o. |
| Applicant(s) |
Cisen Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0DA6B |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014000686 |
| Title |
Pyrimidobenzoazepine Compound and Use Thereof As Antitumour Drug. |
| Abstract |
Disclosed in the present invention are a Pyrimidobenzoazepine compound and the use thereof as an antitumour drug. The advantage of the present invention consists in that the compound and the pharmaceu. |
| Applicant(s) |
Cisen Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0A9RY |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013112959 |
| Title |
Antifibrotic Compounds and Uses Thereof. |
| Abstract |
The present invention provides compounds having the general structural formula (I), and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis. |
| Applicant(s) |
Angion Biomedica Corp |
| Representative Drug(s) |
D05LBH |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013112950 |
| Title |
Certain Chemical Entities, Compositions, and Methods. |
| Abstract |
Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. In another aspect, the present disclosure provides a method of treating a disorder in a subject in need thereof, comprising: a) determining the presence or absence of a B-Raf (BRAF) mutation in a biological sample isolated from the subject; and b) if a BRAF mutation is determined to be present in the subject, administering to the subject a therapeutically effective amount of a compound or pharmaceutically acceptable salt of any one of the compounds described herein. |
| Applicant(s) |
Neupharma, Inc |
| Representative Drug(s) |
D06ARD |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013107225 |
| Title |
N-((4-Chloro-3-Trifluoromethyl)Phenyl)-N'-(2-Fluoro-4-((2-Hydroxymethylaminoformyl)-4-Pyridyloxo)Phenyl)Urea and Use Thereof As Anti-Cancer Drug. |
| Abstract |
The present invention relates to N-((4-chloro-3-trifluoromethyl)phenyl)-N'-(2-fluoro-4-((2-hydroxymethylaminoformyl)-4-pyridyloxo)phenyl)urea used as a VEGFR-2 kinase inhibitor and the use thereof for. |
| Applicant(s) |
Hunan Nonferrous Metals Group Chembio Pharmacy Co., Ltd |
| Representative Drug(s) |
D0XS0Z |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013101954 |
| Title |
3-Phenyl-5-Ureidoisothiazole-4-Carboximide and 3-Amino-5-Phenylisothiazole Derivatives As Kinase Inhibitors. |
| Abstract |
This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D0T1GG |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013097753 |
| Title |
Fused Heterocyclic Derivative and Application Thereof. |
| Abstract |
Provided is a 1,6-naphthyridine-4-ketone fused Heterocyclic derivative, an intermediate thereof, and a preparation method thereof. The derivative has inhibitory activity for various kinases, for example, c-Met, KDR, and c-kit, and moreover, has inhibitory activity for proliferation of various tumour cells. |
| Applicant(s) |
Jiangsu Simcere Pharmaceutical Co Ltd |
| Representative Drug(s) |
D04UKD |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013044362 |
| Title |
Selected Inhibitors of Protein Tyrosine Kinase Activity. |
| Abstract |
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling. |
| Applicant(s) |
Methylgene Inc |
| Representative Drug(s) |
D0BA5J |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013044361 |
| Title |
Inhibitors of Protein Tyrosine Kinase Activity. |
| Abstract |
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling. |
| Applicant(s) |
Methylgene Inc |
| Representative Drug(s) |
D0S4XH |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013040515 |
| Title |
Certain Chemical Entities, Compositions, and Methods. |
| Abstract |
Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described. |
| Applicant(s) |
Neupharma, Inc |
| Representative Drug(s) |
D0BL4H |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013037292 |
| Title |
Substituted Aromatic Urea Compound and Use Thereof As Anti-Cancer Drug. |
| Abstract |
The present invention relates to substituted aromatic urea compounds of formula (I) or (II) as VEGFR-2 kinase inhibitors, and use thereof in preparation of a drug for treating VEGFR-2 mediated disease. |
| Applicant(s) |
Hunan Nonferrous Metals Group Chembio Pharmacy Co., Ltd |
| Representative Drug(s) |
D0VI1V |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013036866 |
| Title |
Itraconazole Analogs and Use Thereof. |
| Abstract |
Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs. |
| Applicant(s) |
The Johns Hopkins University |
| Representative Drug(s) |
D0T9DV |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013015657 |
| Title |
Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same. |
| Abstract |
Provided are a compound of [chemical formula 1] having an angiogenesis inhibitory activity and pharmaceutically acceptable salts thereof, a method for preparing same, and a pharmaceutical composition. |
| Applicant(s) |
Boryung Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D08INZ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012171487 |
| Title |
Aryloxy Quinolines Derivatives and The Treating Use Thereof. |
| Abstract |
Disclosed herein are aryloxy quinolines derivativesand the said compounds are compounds of formula (I) or pharmaceutically acceptable salts thereof or solvates, wherein R1, R2, R3, R4, m, n, X, Z, Ar. |
| Applicant(s) |
Tianjin Longbogen Pharmaceutical Co., Ltd |
| Representative Drug(s) |
D0M2XJ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012161372 |
| Title |
Double-Target Antibody Fused with A Peptide and Use of Same. |
| Abstract |
Disclosed are a double-target antibody, derived from a human monoclonal antibody, that effectively suppresses a signal transduction mechanism for angiogenesis and the propagation of cancer cells by si. |
| Applicant(s) |
Phanmabcine Inc |
| Representative Drug(s) |
D0Y2IV |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012139499 |
| Title |
Urea Compounds As Well As Preparation Methods, Intermediates and Uses Thereof. |
| Abstract |
Disclosed are urea compounds represented by formula I or pharmaceutically acceptable salts, polymorphic forms, solvates or stereoisomers thereof; as well as preparation methods, intermediates and uses. |
| Applicant(s) |
Shanghai Insititute of Pharmaceutical Industry |
| Representative Drug(s) |
D0DI5S |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012125123 |
| Title |
Pericyte Progenitors From Peripheral Blood. |
| Abstract |
Thus, provided herein are pericyte progenitor cells (e.g., isolated pericyte progenitor cells), methods for generating pericyte progenitors in clinically relevant numbers for various applications applying macromolecular crowding during cell culture, and methods of using the pericyte progenitor cells. |
| Applicant(s) |
National University of Singapore |
| Representative Drug(s) |
D09GWR |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012094451 |
| Title |
Novel Ureas for The Treatment and Prevention of Cancer. |
| Abstract |
A compound of Formula (I), salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by multiple kinases, such as raf, VEGFR, PDGFR, FLT-3, and c-Kit. |
| Applicant(s) |
Beta Pharma Canada Inc |
| Representative Drug(s) |
D0A5NC |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012089137 |
| Title |
Arylurea Compound, Intermediate and Use Thereof. |
| Abstract |
Disclosed in the present invention is an arylurea compound represented by formula I, or a pharmaceutically acceptable salt, a polymorph, a solvate or a stereoisomer thereof, and an intermediate and us. |
| Applicant(s) |
Shanghai Institute of Pharmaceutical Industry |
| Representative Drug(s) |
D00ZFY |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012088563 |
| Title |
Vegfr-2-Specific forms of Vegf-D and Vegf-C and Uses Thereof. |
| Abstract |
Amino-terminal truncated forms of Vascular Endothelial Growth Factor-D (VEGF-D) and Vascular Endothelial Growth Factor-C (VEGF-C) which bind to and stimulate Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) but not Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3), and the use of the same in therapeutic applications in which the stimulation of angiogenesis and not lymphangiogenesis is desired. |
| Applicant(s) |
Vegenics Pty Limited |
| Representative Drug(s) |
D0D0AX |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012084683 |
| Title |
Conjugated 3-(Indolyl)- and 3-(Azaindolyl)-4-Arylmaleimide Compounds and Their Use In Tumor Treatment. |
| Abstract |
The present invention relates to 3-(Indolyl)- and 3-(azaindolyl)-4-phenylmaleimide compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, and the physiologically acceptable salts, solvates and solvates of the salts of the compounds of formula (I). The compounds of formula (I) are suitable for treating tumors. |
| Applicant(s) |
Univ Mainz Johannes Gutenberg |
| Representative Drug(s) |
D04PKQ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012028106 |
| Title |
Deuterium-Enriched Heterocyclic Compounds As Kinase Inhibitors. |
| Abstract |
The present invention provides deuterium-enriched heteroaryl-containing urea compounds (I) and use of the same for treating conditions mediated by protein kinase such as. |
| Applicant(s) |
Ascepion Pharmaceuticals, Inc |
| Representative Drug(s) |
D01CKB |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012004631 |
| Title |
Recombinant Antibody Structures Binding To and Blocking The Activity of Vascular Endothelial Growth Factor 2 (Vegfr- 2 /Kdr). |
| Abstract |
Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors. |
| Applicant(s) |
Tubitak Erdag, Berrin |
| Representative Drug(s) |
D0X2BP |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2010066684 |
| Title |
Pyridyloxyindoles Inhibitors of Vegf-R2 and Use Thereof for Treatment of Disease. |
| Abstract |
The invention relates to novel organic compounds of formula (I), and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases. |
| Applicant(s) |
Novartis Ag |
| Representative Drug(s) |
D07ESG |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014201127 |
| Title |
Urea Derivatives As Antiangiogenic Agents. |
| Applicant(s) |
Kala Pharmaceuticals, Inc |
| Representative Drug(s) |
D05WTW |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013181452 |
| Title |
Methods of Treating Cancer Using Pd-L1 Axis Binding Antagonists and Vegf Antagonists. |
| Abstract |
The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. |
| Applicant(s) |
Genentech, Inc |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20140256819 |
| Title |
Preparation of Phenylacrylamides As Pdgf and Vegf Receptors Kinase Inhibitors. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D0I6WJ |
Drug Info
|
IC50 = 460 nM |
[1] |
| Patent ID |
US20169296747 |
| Title |
Piperidylpyrimidine Derivatives As Modulators of Protein Kinase Inhibitors and of Vascular Endothelial Growth Factor Receptor 2. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D0FK5P |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20169233968 |
| Title |
Kinase Inhibitors. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D09KYB |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20160096837 |
| Title |
Preparation of Pyrazolo[1,5-A]Pyrido[3,4-E]Pyrimidine Derivatives As Tyrosine Kinase Inhibitors. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D0V7OF |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20160096832 |
| Title |
Preparation of 7,8-Dihydropyrido[4,3-D]Pyrimidine Derivatives As Tyrosine Kinase Inhibitors. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D05GVV |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20150158854 |
| Title |
Quinazoline Compounds, Method for Preparing The Same and Use Thereof. |
| Applicant(s) |
Development Center for Biotechnology |
| Representative Drug(s) |
D0MA6I |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20140336108 |
| Title |
Thienopyridine Compounds As Tyrosine Kinase Modulators and Their Preparation. |
| Applicant(s) |
Allergan, Inc |
| Representative Drug(s) |
D0D7SL |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20130165458 |
| Title |
Quinazoline Compounds As Kinase Inhibitors. |
| Applicant(s) |
Development Center for Biotechnology |
| Representative Drug(s) |
D0O5IA |
Drug Info
|
N.A. |
[1] |
